BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 32508744)

  • 1. A Novel MAX Gene Mutation Variant in a Patient With Multiple and "Composite" Neuroendocrine-Neuroblastic Tumors.
    Pozza C; Sesti F; Di Dato C; Sbardella E; Pofi R; Schiavi F; Bonifacio V; Isidori AM; Faggiano A; Lenzi A; Giannetta E
    Front Endocrinol (Lausanne); 2020; 11():234. PubMed ID: 32508744
    [No Abstract]   [Full Text] [Related]  

  • 2. Clinical Characterization of the Pheochromocytoma and Paraganglioma Susceptibility Genes SDHA, TMEM127, MAX, and SDHAF2 for Gene-Informed Prevention.
    Bausch B; Schiavi F; Ni Y; Welander J; Patocs A; Ngeow J; Wellner U; Malinoc A; Taschin E; Barbon G; Lanza V; Söderkvist P; Stenman A; Larsson C; Svahn F; Chen JL; Marquard J; Fraenkel M; Walter MA; Peczkowska M; Prejbisz A; Jarzab B; Hasse-Lazar K; Petersenn S; Moeller LC; Meyer A; Reisch N; Trupka A; Brase C; Galiano M; Preuss SF; Kwok P; Lendvai N; Berisha G; Makay Ö; Boedeker CC; Weryha G; Racz K; Januszewicz A; Walz MK; Gimm O; Opocher G; Eng C; Neumann HPH;
    JAMA Oncol; 2017 Sep; 3(9):1204-1212. PubMed ID: 28384794
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MAX mutations status in Swedish patients with pheochromocytoma and paraganglioma tumours.
    Crona J; Maharjan R; Delgado Verdugo A; Stålberg P; Granberg D; Hellman P; Björklund P
    Fam Cancer; 2014 Mar; 13(1):121-5. PubMed ID: 23743562
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Testing new susceptibility genes in the cohort of apparently sporadic phaeochromocytoma/paraganglioma patients with clinical characteristics of hereditary syndromes.
    Pęczkowska M; Kowalska A; Sygut J; Waligórski D; Malinoc A; Janaszek-Sitkowska H; Prejbisz A; Januszewicz A; Neumann HP
    Clin Endocrinol (Oxf); 2013 Dec; 79(6):817-23. PubMed ID: 23551045
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Case Report: Pheochromocytoma and Synchronous Neuroblastoma in a Family With Hereditary Pheochromocytoma Associated With a MAX Deleterious Variant.
    Duarte DB; Ferreira L; Santos AP; Costa C; Lima J; Santos C; Afonso M; Teixeira MR; Carvalho R; Cardoso MH
    Front Endocrinol (Lausanne); 2021; 12():609263. PubMed ID: 33815275
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Temozolomide treatment of a malignant pheochromocytoma and an unresectable MAX-related paraganglioma.
    Ferrara AM; Lombardi G; Pambuku A; Meringolo D; Bertorelle R; Nardin M; Schiavi F; Iacobone M; Opocher G; Zagonel V; Zovato S
    Anticancer Drugs; 2018 Jan; 29(1):102-105. PubMed ID: 29099418
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An update on the genetics of paraganglioma, pheochromocytoma, and associated hereditary syndromes.
    Gimenez-Roqueplo AP; Dahia PL; Robledo M
    Horm Metab Res; 2012 May; 44(5):328-33. PubMed ID: 22328163
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Integrative analysis of miRNA and mRNA expression profiles in pheochromocytoma and paraganglioma identifies genotype-specific markers and potentially regulated pathways.
    de Cubas AA; Leandro-García LJ; Schiavi F; Mancikova V; Comino-Méndez I; Inglada-Pérez L; Perez-Martinez M; Ibarz N; Ximénez-Embún P; López-Jiménez E; Maliszewska A; Letón R; Gómez Graña A; Bernal C; Alvarez-Escolá C; Rodríguez-Antona C; Opocher G; Muñoz J; Megias D; Cascón A; Robledo M
    Endocr Relat Cancer; 2013 Aug; 20(4):477-93. PubMed ID: 23660872
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MAX mutations cause hereditary and sporadic pheochromocytoma and paraganglioma.
    Burnichon N; Cascón A; Schiavi F; Morales NP; Comino-Méndez I; Abermil N; Inglada-Pérez L; de Cubas AA; Amar L; Barontini M; de Quirós SB; Bertherat J; Bignon YJ; Blok MJ; Bobisse S; Borrego S; Castellano M; Chanson P; Chiara MD; Corssmit EP; Giacchè M; de Krijger RR; Ercolino T; Girerd X; Gómez-García EB; Gómez-Graña A; Guilhem I; Hes FJ; Honrado E; Korpershoek E; Lenders JW; Letón R; Mensenkamp AR; Merlo A; Mori L; Murat A; Pierre P; Plouin PF; Prodanov T; Quesada-Charneco M; Qin N; Rapizzi E; Raymond V; Reisch N; Roncador G; Ruiz-Ferrer M; Schillo F; Stegmann AP; Suarez C; Taschin E; Timmers HJ; Tops CM; Urioste M; Beuschlein F; Pacak K; Mannelli M; Dahia PL; Opocher G; Eisenhofer G; Gimenez-Roqueplo AP; Robledo M
    Clin Cancer Res; 2012 May; 18(10):2828-37. PubMed ID: 22452945
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mutation analysis of the SDHB and SDHD genes in pheochromocytomas and paragangliomas: identification of a novel nonsense mutation (Q168X) in the SDHB gene.
    Oishi Y; Nagai S; Yoshida M; Fujisawa S; Sazawa A; Shinohara N; Nonomura K; Matsuno K; Shimizu C
    Endocr J; 2010; 57(8):745-50. PubMed ID: 20505258
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mutational profile and genotype/phenotype correlation of non-familial pheochromocytoma and paraganglioma.
    Albattal S; Alswailem M; Moria Y; Al-Hindi H; Dasouki M; Abouelhoda M; Alkhail HA; Alsuhaibani E; Alzahrani AS
    Oncotarget; 2019 Oct; 10(57):5919-5931. PubMed ID: 31666924
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Novel Phenotype of Germline Pathogenic Variants in
    Chang X; Li Z; Ma X; Cui Y; Chen S; Tong A
    Front Endocrinol (Lausanne); 2020; 11():558. PubMed ID: 32973681
    [No Abstract]   [Full Text] [Related]  

  • 13. Genetics and molecular pathogenesis of pheochromocytoma and paraganglioma.
    Galan SR; Kann PH
    Clin Endocrinol (Oxf); 2013 Feb; 78(2):165-75. PubMed ID: 23061808
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characteristics and genetic testing outcomes of patients with clinically suspected paraganglioma/pheochromocytoma (PGL/PCC) syndrome in Singapore.
    Ting KR; Ong PY; Wei SOG; Parameswaran R; Khoo CM; Deepak DS; Lee SC
    Hered Cancer Clin Pract; 2020 Dec; 18(1):24. PubMed ID: 33308260
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Primary Renal Paragangliomas and Renal Neoplasia Associated with Pheochromocytoma/Paraganglioma: Analysis of von Hippel-Lindau (VHL), Succinate Dehydrogenase (SDHX) and Transmembrane Protein 127 (TMEM127).
    Gupta S; Zhang J; Milosevic D; Mills JR; Grebe SK; Smith SC; Erickson LA
    Endocr Pathol; 2017 Sep; 28(3):253-268. PubMed ID: 28646318
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Paragangliomas/Pheochromocytomas: clinically oriented genetic testing.
    Martins R; Bugalho MJ
    Int J Endocrinol; 2014; 2014():794187. PubMed ID: 24899893
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Multiple Endocrine Tumors Associated with Germline MAX Mutations: Multiple Endocrine Neoplasia Type 5?
    Seabrook AJ; Harris JE; Velosa SB; Kim E; McInerney-Leo AM; Dwight T; Hockings JI; Hockings NG; Kirk J; Leo PJ; Love AJ; Luxford C; Marshall M; Mete O; Pennisi DJ; Brown MA; Gill AJ; Hockings GI; Clifton-Bligh RJ; Duncan EL
    J Clin Endocrinol Metab; 2021 Mar; 106(4):1163-1182. PubMed ID: 33367756
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Paragangliomas: update on differential diagnostic considerations, composite tumors, and recent genetic developments.
    Papathomas TG; de Krijger RR; Tischler AS
    Semin Diagn Pathol; 2013 Aug; 30(3):207-23. PubMed ID: 24144290
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New Insights on the Genetics of Pheochromocytoma and Paraganglioma and Its Clinical Implications.
    Jhawar S; Arakawa Y; Kumar S; Varghese D; Kim YS; Roper N; Elloumi F; Pommier Y; Pacak K; Del Rivero J
    Cancers (Basel); 2022 Jan; 14(3):. PubMed ID: 35158861
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.